Some thoughts on the PR today in relation to my post on Monday, linked above.
Dr. Malan's work involved diagnosing and treatment of many infectious diseases for research and clinical trials to bring them to market. This might have strained QMC in needing to build labs and hire personnel to conduct the research and trials. While royalties from this IP would be valuable, they would be far in the future. When it happens, QMCH will get royalties on its use with these tests, clinical trials and brought to market. To the extent Dr. Malan's work involved costs in setting up his labs and hiring personnel, that risk is gone and licensing and royalties at little or no cost or risk is in place.
If what is lost from Dr. Malan going to Innova is the ability to conduct clinical trials on revolutionary stem cell/quantum dot tests and treatments, what is gained is Dr. Carrano's abilities and experience in bringing "specific diagnostics medical modules" to market. Near term, Innova is hinting at introducing new antigen diagnostic rapid-tests with quantum dots, perhaps multi-functional based on Malan's IP and work. Part of the agreement is that QMCH must be made into a functional product adapted and integrated with Innova's tests. Increasing the functionality of QMCH increases its value to the medical industry and governments who need better information to both diagnose, see trends, and plan for needs.
Dr. Carrano has experience getting product passed by the FDA. I don't know if that helps with the Antigen Test EUA we are waiting to have approved, but would definitely help in future applications to the FDA, by understanding what the FDA needs and wants to see in EUA requests. While the FDA does not "approve" health passports, the reports and figures and conclusions from testing trials submitted with the EUA application could very well use QMCH in the presentation of the application.
Just as important as his ability to lead projects for a Diagnostics startup he founded, is his 28 year military career with time as "a Program Manager at the Defense Advanced Research Projects Agency (DARPA) for 5 years where he initiated and led programs focused on biological sensing and diagnostics." Just like knowing from his experience how to work with the FDA, he also brings that same experience in working with DARPA, and by extension, the rest of the Federal Government. It appears to me that Dr. Carrano fills a better need of QMC's than Dr. Malan, and is therefore an upgrade at this position.
Excerpt from the PR-
Dr. Carrano comes to QMC, from Paratus Diagnostics, where he was most recently the Founder, President and CEO. In this role, Dr. Carrano was focused on developing specific diagnostics medical modules to resolve the obstacle of point-of-care technologies achieving low-complexity (CLIA waived) designation by the FDA. Dr. Carrano has vast experience raising capital in diagnostics, a crucial factor to propel QMC forward as a leader in the industry. Dr. Carrano is a West Point graduate and 28 year veteran of the United States Army. John was a Program Manager at the Defense Advanced Research Projects Agency (DARPA) for 5 years where he initiated and led programs focused on biological sensing and diagnostics. “The unique QMC technology portfolio positions the company at the forefront of disruptive innovation in clinical diagnostics. I am honored to join this team of seasoned and successful professionals as we pursue excellence in transformative solutions for healthcare,” said Dr. Carrano.
Read More: https://investorshangout.com/post/view?id=607...z6o5YQU500
Dr. Malan's work involved diagnosing and treatment of many infectious diseases for research and clinical trials to bring them to market. This might have strained QMC in needing to build labs and hire personnel to conduct the research and trials. While royalties from this IP would be valuable, they would be far in the future. When it happens, QMCH will get royalties on its use with these tests, clinical trials and brought to market. To the extent Dr. Malan's work involved costs in setting up his labs and hiring personnel, that risk is gone and licensing and royalties at little or no cost or risk is in place.
If what is lost from Dr. Malan going to Innova is the ability to conduct clinical trials on revolutionary stem cell/quantum dot tests and treatments, what is gained is Dr. Carrano's abilities and experience in bringing "specific diagnostics medical modules" to market. Near term, Innova is hinting at introducing new antigen diagnostic rapid-tests with quantum dots, perhaps multi-functional based on Malan's IP and work. Part of the agreement is that QMCH must be made into a functional product adapted and integrated with Innova's tests. Increasing the functionality of QMCH increases its value to the medical industry and governments who need better information to both diagnose, see trends, and plan for needs.
Dr. Carrano has experience getting product passed by the FDA. I don't know if that helps with the Antigen Test EUA we are waiting to have approved, but would definitely help in future applications to the FDA, by understanding what the FDA needs and wants to see in EUA requests. While the FDA does not "approve" health passports, the reports and figures and conclusions from testing trials submitted with the EUA application could very well use QMCH in the presentation of the application.
Just as important as his ability to lead projects for a Diagnostics startup he founded, is his 28 year military career with time as "a Program Manager at the Defense Advanced Research Projects Agency (DARPA) for 5 years where he initiated and led programs focused on biological sensing and diagnostics." Just like knowing from his experience how to work with the FDA, he also brings that same experience in working with DARPA, and by extension, the rest of the Federal Government. It appears to me that Dr. Carrano fills a better need of QMC's than Dr. Malan, and is therefore an upgrade at this position.
Excerpt from the PR-
Dr. Carrano comes to QMC, from Paratus Diagnostics, where he was most recently the Founder, President and CEO. In this role, Dr. Carrano was focused on developing specific diagnostics medical modules to resolve the obstacle of point-of-care technologies achieving low-complexity (CLIA waived) designation by the FDA. Dr. Carrano has vast experience raising capital in diagnostics, a crucial factor to propel QMC forward as a leader in the industry. Dr. Carrano is a West Point graduate and 28 year veteran of the United States Army. John was a Program Manager at the Defense Advanced Research Projects Agency (DARPA) for 5 years where he initiated and led programs focused on biological sensing and diagnostics. “The unique QMC technology portfolio positions the company at the forefront of disruptive innovation in clinical diagnostics. I am honored to join this team of seasoned and successful professionals as we pursue excellence in transformative solutions for healthcare,” said Dr. Carrano.
Read More: https://investorshangout.com/post/view?id=607...z6o5YQU500
